- Companies
- Clal Biotechnology
Clal Biotechnology Valuation Multiples
Clal Biotechnology is valued at $11M as of October 2026. In the last fiscal year, Clal Biotechnology EBITDA was ($7M).
Clal Biotechnology Overview
About Clal Biotechnology
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.
Founded
1998
HQ
Employees
N/A
Website
Sectors
Financials (Last FY)
EV
$17M
Valuation Multiples
Start free trialClal Biotechnology Financials
Clal Biotechnology reported last fiscal year revenue of - and negative EBITDA of ($7M).
In the same fiscal year, Clal Biotechnology generated ($7M) in EBITDA losses and had net loss of ($4M).
Clal Biotechnology P&L
In the most recent fiscal year, Clal Biotechnology reported revenue of - and EBITDA of ($7M).
Clal Biotechnology is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Clal Biotechnology Stock Performance
Clal Biotechnology has current market cap of $11M, and enterprise value of $17M.
Market Cap Evolution
Clal Biotechnology's stock price is $0.07.
Clal Biotechnology has an EPS (earnings per share) of $-0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17M | $11M | -9.2% | - | - | - | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialClal Biotechnology Valuation Multiples
Clal Biotechnology trades at (2.5x) EV/EBITDA.
Clal Biotechnology Financial Valuation Multiples
As of October 20, 2026, Clal Biotechnology has market cap of $11M and EV of $17M.
Clal Biotechnology has a P/E ratio of (2.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Clal Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Clal Biotechnology Competitors
Clal Biotechnology competitors include Hub Girişim, Bio Meat Foodtech, CodeLab Capital, Unfold.vc, Azevedo & Travassos Energia, Netcapital, Tern, ICU Girisim Sermayesi, Next Dynamics and HYLQ Strategy.
Most Clal Biotechnology public comparables operate across PE & VC.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $44K | ($11M) | 258.5x | - | (1.0x) | - | |||
| - | - | - | - | - | - | |||
| $1M | ($1M) | 7.7x | - | (6.8x) | - | |||
| ($1M) | ($1M) | (8.3x) | - | (6.6x) | - | |||
| $567K | ($830K) | 18.9x | - | (12.9x) | - | |||
| $869K | ($28M) | 16.6x | - | (0.5x) | - | |||
| $72K | ($7M) | 179.2x | - | (1.9x) | - | |||
| - | ($4M) | - | - | (2.1x) | - | |||
This data is available for Pro users. Sign up to see all Clal Biotechnology competitors and their valuation data. Start Free Trial | ||||||||
Investments by Clal Biotechnology
Clal Biotechnology has invested in 11 companies to date.
Latest investment by Clal Biotechnology was on August 3rd 2023. Clal Biotechnology invested in TytoCare in their $49M Series E round (EV/Revenue multiple available to Pro users).
Latest Investments by Clal Biotechnology
| Description | TytoCare is a Tel Aviv-headquartered digital health company offering remote examination devices and telehealth platforms. TytoHome enables consumer self-exams of heart, lungs, skin, throat, ears, and temperature, while TytoPro supports clinicians and TytoClinic serves clinics. The system includes AI-guided tools, video consultations, and cloud analytics, used by over 1,000 healthcare organizations globally. | Sight Diagnostics is a Jerusalem-headquartered medtech company developing AI-powered blood analyzers. Its OLO device, FDA 510(k)-cleared in 2020, performs complete blood counts from finger-prick samples in minutes using digital microscopy. Previously, Parasight conducted nearly one million malaria tests in 24 countries. Sight maintains commercial operations across five continents with offices in London and New York. | Cambridge, Massachusetts-based Cadent Therapeutics develops precision neuroscience drugs that modulate brain rhythms for neurological disorders. Founded in 2010, the company targets movement and cognitive impairments with first-in-class molecules combining target-specific design, patient stratification, and quantitative endpoints. Its pipeline addresses Parkinson's disease and other brain rhythm dysfunctions. | Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. | |
| HQ Country | |||||
| HQ City | New York City, NY | Tel Aviv | - | - | |
| Deal Date | 3 Aug 2023 | 5 Aug 2020 | 29 Apr 2020 | 2 Oct 2019 | |
| Round | Series E | Series D | Series B | Series B | |
| Raised | $49M | $71M | $15M | $33M | |
| Investors | MemorialCare Innovation Fund; Healthcare of Ontario Pension Plan (HOOPP); Clal Biotechnology; Insight Partners | New Alliance Capital; Koch Disruptive Technologies; OurCrowd; Clal Biotechnology; Longliv Ventures; GO CAPITAL | Cowen Healthcare Investments; Novartis; Access Industries; Qiming Venture Partners; Atlas Venture; Clal Biotechnology | EFung Capital; Clal Biotechnology; Livzon Pharmaceutical Group | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Clal Biotechnology investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Clal Biotechnology
| When was Clal Biotechnology founded? | Clal Biotechnology was founded in 1998. |
| Where is Clal Biotechnology headquartered? | Clal Biotechnology is headquartered in Israel. |
| Is Clal Biotechnology publicly listed? | Yes, Clal Biotechnology is a public company listed on Tel Aviv Stock Exchange. |
| What is the stock symbol of Clal Biotechnology? | Clal Biotechnology trades under CBI ticker. |
| When did Clal Biotechnology go public? | Clal Biotechnology went public in 2007. |
| Who are competitors of Clal Biotechnology? | Clal Biotechnology main competitors include Hub Girişim, Bio Meat Foodtech, CodeLab Capital, Unfold.vc, Azevedo & Travassos Energia, Netcapital, Tern, ICU Girisim Sermayesi, Next Dynamics, HYLQ Strategy. |
| What is the current market cap of Clal Biotechnology? | Clal Biotechnology's current market cap is $11M. |
| Is Clal Biotechnology profitable? | No, Clal Biotechnology is not profitable. |
| How many companies Clal Biotechnology has acquired to date? | Clal Biotechnology hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Clal Biotechnology has invested to date? | As of October 2026, Clal Biotechnology has invested in 11 companies. |
| What was the last Clal Biotechnology investment? | On 3rd August 2023 Clal Biotechnology invested in TytoCare, participating in a $49M Series E round, alongside MemorialCare Innovation Fund, Healthcare of Ontario Pension Plan (HOOPP), and Insight Partners. |
See public comps similar to Clal Biotechnology
Lists including Clal Biotechnology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




